AFQ056 Treatment of Levodopa-Induced Dyskinesias: Results of 2 Randomized Controlled Trials

被引：150

作者：

Berg, Daniela ^{[2
,3
]}

Godau, Jana ^{[2
,3
]}

Trenkwalder, Claudia ^{[4
,5
]}

Eggert, Karla ^{[6
]}

Csoti, Iiona ^{[7
]}

Storch, Alexander ^{[8
]}

Huber, Heiko ^{[2
,3
]}

Morelli-Canelo, Monica ^{[4
,5
]}

Stamelou, Maria ^{[6
]}

Ries, Vincent ^{[6
]}

Wolz, Martin ^{[8
]}

Schneider, Christine ^{[8
]}

Di Paolo, Therese ^{[9
,10
]}

Gasparini, Fabrizio ^{[1
]}

Hariry, Sam ^{[1
]}

Vandemeulebroecke, Marc ^{[11
]}

Abi-Saab, Walid ^{[1
]}

Cooke, Katy ^{[12
]}

Johns, Donald ^{[1
]}

Gomez-Mancilla, Baltazar ^{[1
]}

机构：

[1] Novartis Pharma AG, Neurosci Discovery, CH-4002 Basel, Switzerland

[2] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany

[3] German Ctr Neurodegenerat Dis, Tubingen, Germany

[4] Univ Gottingen, D-3400 Gottingen, Germany

[5] Paracelsus Elena Klin, Kassel, Germany

[6] Univ Marburg, Marburg, Germany

[7] Gertrudis Klin, Biskirchen, Germany

[8] Tech Univ Dresden, Dept Neurol, D-8027 Dresden, Germany

[9] Univ Laval, Med Ctr, Mol Endocrinol & Genom Res Ctr, Quebec City, PQ, Canada

[10] Univ Laval, Fac Pharm, Quebec City, PQ, Canada

[11] Novartis Pharma AG, Translat Sci Biostat, CH-4002 Basel, Switzerland

[12] Alpha Plus Med Commun Ltd, High Wycombe, Bucks, England

来源：

MOVEMENT DISORDERS | 2011年 / 26卷 / 07期

关键词：

parkinsonism; levodopa; glutamate antagonists; dyskinesias; METABOTROPIC GLUTAMATE RECEPTORS; DOPA-INDUCED DYSKINESIAS; PARKINSONS-DISEASE; MONKEYS; ANTAGONIST; MODEL; AMANTADINE; BLOCKADE;

D O I：

10.1002/mds.23616

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Study objectives were to assess the efficacy, safety, and tolerability of AFQ056 in Parkinson's disease patients with levodopa-induced dyskinesia. Two randomized, double-blind, placebo-controlled, parallel-group, in-patient studies for Parkinson's disease patients with moderate to severe levodopa-induced dyskinesia (study 1) and severe levodopa-induced dyskinesia (study 2) on stable dopaminergic therapy were performed. Patients received 25-150 mg AFQ056 or placebo twice daily for 16 days (both studies). Study 2 included a 4-day down-titration. Primary outcomes were the Lang-Fahn Activities of Daily Living Dyskinesia Scale (study 1), the modified Abnormal Involuntary Movement Scale (study 2), and the Unified Parkinson's Disease Rating Scale-part III both studies). Secondary outcomes included the Unified Parkinson's Disease Rating Scale-part IV items 32-33. The primary analysis was change from baseline to day 16 on all outcomes. Treatment differences were assessed. Fifteen patients were randomized to AFQ056 and 16 to placebo in study 1; 14 patients were randomized to each group in study 2. AFQ056-treated patients showed significant improvements in dyskinesias on day 16 versus placebo (eg, Lang-Fahn Activities of Daily Living Dyskinesia Scale, P = .021 [study 1]; modified Abnormal Involuntary Movement Scale, P = .032 [study 2]). No significant changes were seen from baseline on day 16 on the Unified Parkinson's Disease Rating Scale-part III in either study. Adverse events were reported in both studies, including dizziness. Serious adverse events (most commonly worsening of dyskinesias, apparently associated with stopping treatment) were reported by 4 AFQ056-treated patients in study 1, and 3 patients (2 AFQ056-treated patient and 1 in the placebo group) in study 2. AFQ056 showed a clinically relevant and significant antidyskinetic effect without changing the antiparkinsonian effects of dopaminergic therapy. (C) 2010 Movement Disorder Society

引用

页码：1243 / 1250

页数：8

共 19 条

[1] [Anonymous], DHEW PUBL
[2] Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD
Bibbiani, F
Oh, JD
Kielaite, A
Collins, MA
Smith, C
Chase, TN
[J]. EXPERIMENTAL NEUROLOGY, 2005, 196 (02) : 422 - 429
[3] Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism
Chase, TN
Oh, JD
[J]. TRENDS IN NEUROSCIENCES, 2000, 23 (10) : S86 - S91
[4] Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease
Dekundy, A
Pietraszek, M
Schaefer, D
Cenci, MA
Danysz, W
[J]. BRAIN RESEARCH BULLETIN, 2006, 69 (03) : 318 - 326
[5] Levodopa-induced dyskinesias
Fabbrini, Giovanni
Brotchie, Jonathan M.
Grandas, Francisco
Nomoto, Masahiro
Goetz, Christopher G.
[J]. MOVEMENT DISORDERS, 2007, 22 (10) : 1379 - 1389
[6] Fahn S., 1987, RECENT DEV PARKINSON, V2
[7] EFFECT OF NONDOPAMINERGIC DRUGS ON L-DOPA-INDUCED DYSKINESIAS IN MPTP-TREATED MONKEYS
GOMEZMANCILLA, B
BEDARD, PJ
[J]. CLINICAL NEUROPHARMACOLOGY, 1993, 16 (05) : 418 - 427
[8] Groiss S J, 2009, Ther Adv Neurol Disord, V2, P20, DOI 10.1177/1756285609339382
[9] Jankovic Joseph, 2008, Neuropsychiatr Dis Treat, V4, P743
[10] Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease
Johnston, Tom H.
Fox, Susan H.
McIldowie, Matthew J.
Piggott, Matthew J.
Brotchie, Jonathan M.
[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 333 (03) : 865 - 873

← 1 2 →